ALTSTATION.IO

Agilent Technologies, Inc. (A) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$130.22

Change

+0.45%

Market Cap

$36.92B

Avg Volume

2.0M

Company Overview

Agilent Technologies, Inc. provides tailored solutions primarily for the life sciences, diagnostics, and applied chemical sectors. The company offers a wide range of products, including liquid chromatography and mass spectrometry systems, consumables, and software solutions that support laboratories in managing data and workflows. Its primary customers include pharmaceutical companies, hospitals, research institutions, and environmental organizations that rely on Agilent’s technology for research, diagnostics, and regulatory compliance.

Agilent holds a strong position as a market leader in the diagnostics and research space. They have a competitive edge due to their extensive product portfolio and strong focus on innovation. However, they face challenges from competitors like Thermo Fisher Scientific and Roche, who also have significant market share and advanced technologies. The competitive landscape demands constant innovation and efficiency, with pressure to reduce costs while improving performance.

Currently, Agilent is in a growth phase, bolstered by increased demand for diagnostics and life sciences tools, especially in genomic testing and biopharmaceutical development. They continue to expand their service offerings and invest in new technologies, evidenced by their recent acquisition of the software company BioTek Instruments. This strategic shift aligns with rising trends in automation and data integration, positioning Agilent well for future opportunities in an evolving market.

Key Financials

Market Cap

$36.92B

Revenue

$6.95B

EBITDA

$1.96B

Gross Margin

52.4%

Profit Margin

18.8%

Revenue Growth

9.4%

Total Cash

$1.79B

Total Debt

$3.54B

Free Cash Flow

$998.50M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

28.43

Forward P/E

19.88

Beta

1.30

52-Week High

$160.27

52-Week Low

$96.43

EPS

$4.58

50-Day Avg

$141.46

200-Day Avg

$128.39

Price/Book

5.47

Technical Analysis

Over the past 52 weeks, Agilent Technologies, Inc. (A) has exhibited a downward trend, with the most significant declines occurring since reaching a peak in February near $140. The stock is now trading at $130.22, suggesting it has moved close to key support at $129.58, which was previously tested multiple times in recent months. Resistance is noted at the $140 level, which aligns with the February peak and has shown to be a barrier for upward movements. The recent price action indicates a loss of momentum, with the stock trending lower over the last few weeks after failing to sustain gains above $140. Currently, the price is positioned within the 52-week range but is only slightly above the established support, implying potential vulnerability if selling pressure continues. The negative 9.1% change over this period reinforces the overall bearish sentiment that has been present.

Recent News and Developments

Here are the latest news and developments for Agilent Technologies, Inc

(A) stock from the past week (January 31, 2026, to February 7, 2026):

Market Update

### Agilent Showcases New Automation and AI Lab Tools at SLAS2026 Conference

Market Update

Agilent Technologies is presenting its next-generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, running from February 7–11, 2026, in Boston. The company is highlighting an expanded automation ecosystem that integrates advanced imaging, software, robotics, and AI-powered optimization to enhance efficiency and data quality in laboratories. This showcase i

Market Sentiment and Analyst Recommendations

Bull Case

Agilent is firing on the right cylinders. Revenue growth at 9.4% is solid for a company this size, and the recent product announcements at SLAS2026 show real innovation momentum in automation and AI-powered lab tools. Wall Street isn’t messing around here—18 analysts rate this a buy with a median target of $170, implying 27.8% upside from current levels. The company beat earnings expectations last quarter (EPS $1.59 vs $1.58 estimate) and is trading at a 28.43 P/E, which is reasonable for a high-quality industrial with consistent execution. More importantly, the cash position ($1.79B) covers nearly half the debt load ($3.54B), giving the company flexibility for dividends, buybacks, or strategic investments in the automation space where they’re gaining traction.

Bear Case

The stock is down 12% in 30 days and sitting right on support at $129.58, which signals investor hesitation despite the bullish analyst consensus. A P/E of 28.43 isn’t cheap—you’re paying a premium multiple for a company growing at 9.4%, which means the market is pricing in acceleration that hasn’t materialized yet. The debt-to-cash ratio is concerning; with $3.54B in debt against $1.79B in cash, Agilent has meaningful leverage that limits financial flexibility if growth stumbles. The recent price action tells the real story: the stock peaked near $160 and has been unable to sustain those levels, suggesting institutional investors are taking profits. If Q1 FY2026 earnings disappoint on February 25, this support level breaks and you’re looking at a test of $96.43 or lower.

What to Watch

The February 25 earnings call is the pivotal event. Investors need to see whether Q1 revenue growth accelerates or declines—9.4% is the baseline, but the market wants to see 10%+ to justify the current valuation. Watch the guidance. If Agilent walks down full-year expectations, the analyst consensus will crack fast. The SLAS2026 product announcements (happening now through February 11) need to translate into actual pipeline wins; monitor press releases for customer adoption or contract wins in the automation and AI software space over the next 60 days. Price action is critical—if the stock holds above $129.58 through earnings and closes above $140 afterward, the bull case gains traction. A break below $129.58 on weak earnings invalidates the entire thesis and could trigger a 15-20% selloff to the $110 range.

Analyst Consensus

BUY

Based on 18 analyst opinions

Low Target

$150.00

Mean Target

$169.67

High Target

$185.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

18,100

Earnings & Dividends

Next Earnings

Feb 25, 2026

EPS (Trailing)

$4.58

Dividend Yield

79.0%

Payout Ratio

21.7%

Frequently Asked Questions

Is Agilent Technologies (A) a good stock to buy?

Analysts are recommending a “BUY” with a target price of $169.67, which suggests a potential upside of about 30% from the current price of $130.22. Given its strong market cap of $36.92B and solid fundamentals, it presents a compelling investment opportunity.

What is the dividend yield for Agilent Technologies?

Agilent Technologies has a high dividend yield of 79.0%. This makes it attractive for income-focused investors looking for consistent returns alongside capital appreciation.

What is Agilent’s price-to-earnings (P/E) ratio?

Agilent’s current P/E ratio stands at 28.43, with a forward P/E of 19.88. This indicates that the stock might be fairly valued compared to its growth potential in the healthcare diagnostics industry.

What has been Agilent’s stock performance over the past year?

The stock has fluctuated between $96.43 and $160.27 over the last 52 weeks. This volatility reflects the market’s careful consideration of its growth outlook amidst sector trends and economic conditions.

Does Agilent Technologies have a solid market position?

Yes, Agilent operates in the Diagnostics & Research sector with a market cap of $36.92B, indicating a strong presence. Its consistent focus on innovation and product development positions the company for continued growth in a competitive landscape.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.